KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)

Core Insights - The article highlights that KEY + WEL as adjuvant therapy significantly reduced the risk of disease recurrence or death compared to KEYTRUDA monotherapy in certain patients with earlier-stage renal cell carcinoma (RCC) [1] Group 1 - The combination of KEY + WEL demonstrated a notable improvement in patient outcomes for those with earlier-stage RCC [1] - The study suggests that this combination therapy could be a more effective treatment option compared to the existing standard of care, KEYTRUDA [1]